Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Genomic Health to Present Studies at the American Society of Clinical Oncology 2009 Breast Cancer Symposium

October 6, 2009

REDWOOD CITY, Calif., Oct. 6 /PRNewswire-FirstCall/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from two studies at the American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium, taking place October 8 through October 10 at the San Francisco Marriott in San Francisco, California. Both studies analyze Oncotype DX®, the company’s multi-gene expression test that physicians use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.

    Presentation details are as follows (all times are Pacific Daylight Time):

     - Friday, October 9 (12:30 p.m. - 1:30 p.m. PT and 5:30 p.m. - 7 p.m. PT)
       Poster Board #A15
       Poster presentation: "Biopsy Cavities in Breast Cancer Specimens:
       Impact on Gene Expression Profiles and Recurrence Risk Assessment"
       Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer
       Center at the University of California, San Francisco
       Location: Golden Gate Hall

     - Friday, October 9 (12:30 p.m. - 1:30 p.m. PT and 5:30 p.m. - 7 p.m. PT)
       Poster Board #A19
       Poster Presentation: "A Study of the Oncotype DX(R) Recurrence Score(R)
       as a Prognostic Factor in Early Stage Breast Cancer in the Japanese
       Population"
       Presenter: Masakazu Toi, M.D., Ph.D, Department of Surgery, Graduate
       School of Medicine, Kyoto University
       Location: Golden Gate Hall

About Oncotype DX®

The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer assay has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of May 2009, more than 8,000 physicians had ordered more than 100,000 tests in over 40 countries, and both Medicare and private health plans covering over 90 percent of U.S. insured lives, provide reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in early 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company’s tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.


Source: newswire